O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is Alabama’s only cancer center designated by the National Cancer Institute and is a national leader in driving cancer research, advancing new cancer treatments, engaging communities in cancer prevention and early detection initiatives, and training the next generation of cancer physicians and scientists. Since it was established in 1971, the Cancer Center has been continuously funded for 48 years and has become a world-renowned institution for cancer research, cancer care and the delivery of that care to all people.

Click here for YouTube channel

Connect with us:

Latest from O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham


Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer

March 20, 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

Exploration of ADCs Highlights the Drive for Personalized Treatment in Ovarian Cancer

October 26, 2022

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

Scarinci Will Be Recognized for Dedicated Efforts to Eliminate Cervical Cancer

July 27, 2022

TogetHER for Health is honoring the contributions of the University of Alabama at Birmingham’s Isabel Scarinci, PhD, with the first-ever Trailblazer Award for her tireless dedication to saving women’s lives both in Alabama and across the world.

Parsaclisib Elicits Impressive Activity in Relapsed/Refractory MCL

December 20, 2021

The potent, highly selective, next-generation PI3Kδ inhibitor parsaclisib demonstrated activity and an acceptable safety profile in patients with Bruton tyrosine kinase inhibitor-naïve relapsed/refractory mantle cell lymphoma.

Questions Remain as CAR T-Cell Therapy Prepares to Transform Relapsed/Refractory Myeloma Treatment

August 24, 2020

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.